Category: Baxter International
Baxter bests analysts' forecasts for its 4th-quarter results but issues a cautious outlook for the 1st quarter.
China closes out an anti-dumoing probe into foreign dialysis kit makers including Fresenius, Nikkiso and Nipro.
The FDA slaps a Class I recall label on Baxter International's pullback of tainted containers used to prepare intravenous medicines.
Baxter's (NYSE:BAX) recall of tainted containers used to prepare intravenous medicines is drawing heightened FDA scrutiny. The regulatory agency slapped a Class I label on the effort, its most serious designation.
A look at the top 10 politicial action committee donations shows that medtech is betting heavily on a GOP win in the midterm elections.
The medical device industry is betting on a Republican sweep of the U.S. Congress during the 2014 mid term elections, according to a MassDevice.com analysis of donations made by the industry's 10 largest political action committees.
Baxter's 3rd-quarter profits beat expectations, driven by its medical product business, but shares slide on a lowered earnings forecast.
(Reuters) - Medical device and drug maker Baxter (NYSE:BAX) reported a higher-than-expected quarterly profit, as sales in its medical products business continued to grow.
Baxter International confirmed Cambridge, Mass., as the new R&D hub for Baxalta, the planned spinout of its biopharmaceuticals business.
Baxter's has 'high' hopes for its coming Baxalta spinout, which will get a full visual work-up before the company goes live mid-2015.
Baxter (NYSE:BAX) crept a little closer to spinning out its biopharmaceuticals division into an independent entity by giving the company a name: Baxalta.